These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24128821)

  • 1. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
    Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
    J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
    Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
    Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
    Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
    J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
    Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
    J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning.
    Prieto I; Pardo J; Luna J; Marin JP; Olivera J; Garcia AJ; Perez AM
    Scand J Pain; 2016 Apr; 11():52-58. PubMed ID: 28850470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.
    Bossi P; Locati L; Bergamini C; Mirabile A; Granata R; Imbimbo M; Resteghini C; Licitra L
    Oral Oncol; 2014 Sep; 50(9):884-7. PubMed ID: 25001894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer.
    Torres LM; Revnic J; Knight AD; Perelman M
    J Palliat Med; 2014 Oct; 17(10):1150-7. PubMed ID: 25211772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
    Perelman M; Knight A
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl pectin nasal spray in breakthrough cancer pain.
    Taylor D; Galan V; Weinstein SM; Reyes E; Pupo-Araya AR; Rauck R;
    J Support Oncol; 2010; 8(4):184-90. PubMed ID: 20822038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
    Portenoy RK; Burton AW; Gabrail N; Taylor D;
    Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
    Chen C; Bujanover S; Gupta A
    J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Taylor DR; Gabrail N
    Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer.
    Lyseng-Williamson KA
    CNS Drugs; 2011 Jun; 25(6):511-22. PubMed ID: 21649451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
    Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
    Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of breakthrough cancer pain (BCP).
    Escobar Y; Mañas A; Juliá J; Gálvez R; Zaragozá F; Margarit C; López R; Casas A; Antón A; Cruz JJ
    Clin Transl Oncol; 2013 Jul; 15(7):526-34. PubMed ID: 23263914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.